At the moment, the gold standard option for diagnosing prostate cancer is the measurement of prostate-specific antigen (PSA) in serum (as a prostate cancer biomarker), which is severely questioned due to the increasing number of unnecessary interventions in stunted or slow-growing tumors that increase patients’ general health and anxiety [26]. This evidence concerns the gene KLK3 and prostate carcinoma.